MLH1 and neoplasm: We found three areas with pervasive gaps: missing dMMR/MSI test records at five of seven hospitals (overall ~ 1 in 10 patients); missing follow-up testing of patients with MLH1 loss at five hospitals (overall ~ 1 in 5 of patients with MLH1 loss); missing record of referral to genetics services for ~ 1 in 2 patients with tumour testing complete and indicating high LS risk.